Cancer organoid applications to investigate chemotherapy resistance

Kenji Harada; Naoya Sakamoto

doi:10.3389/fmolb.2022.1067207

Cancer organoid applications to investigate chemotherapy resistance

Front Mol Biosci. 2022 Dec 13:9:1067207. doi: 10.3389/fmolb.2022.1067207. eCollection 2022.

Authors

Kenji Harada^{1

2}, Naoya Sakamoto²

Affiliations

¹ Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
² Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Abstract

In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique that simulates the in vivo environment in vitro, especially in the quickly developing fields of anticancer drug resistance, drug-tolerant persisters, and drug screening. This review provides an overview of organoid technology, the use of organoids in the field of anticancer drug resistance research, their relevance to clinical information and clinical trials, and approaches to automation and high throughput.

Keywords: cancer; drug resistance; drug screening; drug-tolerant persisters; organoid; precision medicine.

Publication types

Review